EUVIMEDEUVIMED entdecken
Crossref

A Newly Synbiotic Combination Alleviates Obesity by Modulating the Gut Microbiota–Fat Axis and Inhibiting the Hepatic TLR4/NF‐κB Signaling Pathway

Yongbo Kang iD, Peng Ren, Xiaorong Shen, Xiaoyu Kuang, Xiaodan Yang, Haixia Liu, Huan Yan, Hao Yang, Xing Kang, Zeyuan Ding, Xuguang Luo, Jieqiong Ma und 2 weitere

Molecular Nutrition & Food Research · 2023

DOI: 10.1002/mnfr.202300141 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Nutrition & Food Research, 2023. Verfasst von Yongbo Kang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, School of Basic Medical Sciences, Shanxi Medical University, Taiyuan, Shanxi, 030001, China. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Synbiotics, Non-alcoholic Fatty Liver Disease, Metabolic Diseases. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 98 Literaturangaben. Gefördert von: Shanxi Scholarship Council of China, Shanxi Province Natural Science Foundation, Science Research Start-up Fund for Doctor of Shanxi Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Scope Obesity has been recognized as a worldwide public health crisis, this is accompanied by dysregulation of the intestinal microbiota and upregulation of liver steatosis and adipose inflammation. Synbiotic as a novel alternative therapy for obesity have recently gained much attention.

Methods

This study innovatively research the anti‐obesity properties of a newly synbiotic composed of Lactobacillus acidophilus, Bifidobacterium infantis and konjac glucomannan oligosaccharides.

Results

The synbiotic treatment can reduce body weight, fat mass, blood sugar, liver steatosis and adipose inflammation in obesity mice fed by high‐fat diet (HFD). Meanwhile, synbiotic treatment activated brown adipose tissue and improve energy, glucose and lipid metabolism. In addition, synbiotic treatment not solely enhanced the protection of intestinal barrier, but also ameliorated gut microbiota dysbiosis directly by enhancing beneficial microbes and reducing potentially harmful bacteria. Furthermore, the microbiome phenotype and functional prediction showed that synbiotic treatment can improve the gut microbiota functions involving inflammatory state, immune response, metabolism and pathopoiesia.

Conclusion

The synbiotic may be an effective candidate treatment strategy for the clinical prevention and treatment of obesity and other associated metabolic diseases such as hyperlipidemia, nonalcoholic fatty liver diseases by alleviating inflammatory response, regulating energy metabolism and maintaining the balance of intestinal microecology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal MicrobiomeSynbioticsNon-alcoholic Fatty Liver DiseaseMetabolic DiseasesMiceAnimalsNF-kappa BToll-Like Receptor 4ObesitySignal TransductionInflammationDiet, High-FatMice, Inbred C57BL

Stichwörter der Autor:innen

a newly synbiotic combinationenergy metabolismgut microbiotainflammatory responseintestinal permeabilitylipopolysaccharidesobesity

Substanzen

NF-kappa BToll-Like Receptor 4

Autor:innen und Institutionen

  • Department of Microbiology and Immunology, School of Basic Medical Sciences, Shanxi Medical University, Taiyuan, Shanxi, 030001, China.
  • Laboratory of Morphology, Shanxi Medical University, Taiyuan, Shanxi, 030001, China.
  • Department of Endocrinology, Affiliated Hospital of Yunnan University, Kunming, Yunnan, 650021, China.

ORCID-Profile: Yongbo Kang

Förderung

  • Shanxi Scholarship Council of China
  • Shanxi Province Natural Science Foundation
  • Science Research Start-up Fund for Doctor of Shanxi Medical University
  • Science Research Start-up Fund for Doctor of Shanxi Province
  • Scientific and Technological Innovation Programs of Higher Education Institutions in Shanxi
  • Shanxi Province Science Foundation for Youths
  • Natural Science Foundation of Shanxi Province

Zitieren

APA

Kang, Y., Ren, P., Shen, X., Kuang, X., Yang, X., Liu, H., Yan, H., Yang, H., Kang, X., Ding, Z., Luo, X., Ma, J., Yang, Y., & Fan, W. (2023). A Newly Synbiotic Combination Alleviates Obesity by Modulating the Gut Microbiota–Fat Axis and Inhibiting the Hepatic TLR4/NF‐κB Signaling Pathway. Molecular Nutrition & Food Research. https://doi.org/10.1002/mnfr.202300141

Vancouver

Kang Y, Ren P, Shen X, Kuang X, Yang X, Liu H, et al. A Newly Synbiotic Combination Alleviates Obesity by Modulating the Gut Microbiota–Fat Axis and Inhibiting the Hepatic TLR4/NF‐κB Signaling Pathway. Molecular Nutrition & Food Research. 2023. doi:10.1002/mnfr.202300141

BibTeX
@article{Kang2023,
  author = {Kang, Yongbo and Ren, Peng and Shen, Xiaorong and Kuang, Xiaoyu and Yang, Xiaodan and Liu, Haixia and Yan, Huan and Yang, Hao and Kang, Xing and Ding, Zeyuan and Luo, Xuguang and Ma, Jieqiong and Yang, Ying and Fan, Weiping},
  title = {A Newly Synbiotic Combination Alleviates Obesity by Modulating the Gut Microbiota–Fat Axis and Inhibiting the Hepatic TLR4/NF‐κB Signaling Pathway},
  journal = {Molecular Nutrition & Food Research},
  year = {2023},
  doi = {10.1002/mnfr.202300141}
}
Kostenlos starten →